Susceptibility of Candida Species Isolated From HIV Infected and Newborn Candidaemia Patients to Amphotericin B

Similar documents
Candida albicans 426 (64.0 ) C. albicans non-albicans

1* 1. Vijaya S. Rajmane, Shivaji T. Mohite

Table 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.

Antifungal susceptibility testing: Which method and when?

Voriconazole. Voriconazole VRCZ ITCZ

Received 31 March 2009/Returned for modification 26 May 2009/Accepted 22 June 2009

PREVALANCE OF CANDIDIASIS IN CHILDREN IN MUMBAI

PREVALANCE OF CANDIDIASIS IN CHILDREN IN MUMBAI

Rapid Identification and Antifungal Susceptibility Pattern of Candida Isolates from Critically Ill Patients with Candiduria

Received 13 September 2006/Returned for modification 6 November 2006/Accepted 26 December 2006

MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS

An Update in the Management of Candidiasis

Received 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011

SYNERGISTIC ACTIVITIES OF TWO PROPOLIS WITH AMPHOTERICIN B AGAINST SOME AZOLE-RESISTANT CANDIDA STRAINS. PART II

International Journal of Health Sciences and Research ISSN:

Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique

Update zu EUCAST 2012 Cornelia Lass-Flörl

Isolates from a Phase 3 Clinical Trial. of Medicine and College of Public Health, Iowa City, Iowa 52242, Wayne, Pennsylvania ,

Received 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009

Species distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002

Sensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure

Fungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia

Comparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species

WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?

dida tropicalis, Candida parapsilosis, Candida krusei, Cr. neoformans

Antifungal Activity of Voriconazole on Local Isolates: an In-vitro Study

on November 3, 2018 by guest

Received 21 July 2008/Accepted 3 September 2008

Received 25 September 2006/Returned for modification 4 December 2006/Accepted 26 December 2006

Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences

Antifungal Susceptibility Testing

your lab focus susceptibility testing of yeasts and moulds as well as the clinical implications of in vitro antifungal testing.

1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans

Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013

About the Editor Gerri S. Hall, Ph.D.

Updated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017

Antifungal Pharmacotherapy

International Journal of Health Sciences and Research ISSN:

Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species

Case Studies in Fungal Infections and Antifungal Therapy

Received 22 November 2007/Returned for modification 29 December 2007/Accepted 12 January 2008

Echinocandin Susceptibility Testing of Candida Isolates Collected during a 1-Year Period in Sweden

Fungal Infection in the ICU: Current Controversies

Antifungal Susceptibility of Bloodstream Candida Isolates in Pediatric Patients

Received 26 July 2006/Returned for modification 10 October 2006/Accepted 16 October 2006

ANA ESPINEL-INGROFF* Division of Infectious Diseases, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia

CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR

The incidence of invasive fungal infections

Speciation of Candida Isolated from Various Clinical Samples and their Antifungal Susceptibility Profile in a Tertiary Care Hospital

Amphotericin B, antifungal susceptibility, bloodstream infections, Candida spp., posaconazole, sus-

ISSN Vol.02,Issue.19, December-2013, Pages:

ORIGINAL ARTICLE /j x

on December 9, 2018 by guest

Species Distribution and Antifungal Drug Susceptibility of Candida in Clinical Isolates from a Tertiary Care Centre at Bareilly

Terapia della candidiasi addomaniale

Japan Antifungal Surveillance Program (1):

Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-aids patients in Southeast China

WHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU?

Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing

Int.J.Curr.Microbiol.App.Sci (2014) 3(10)

Received 4 August 2010/Returned for modification 23 October 2010/Accepted 19 November 2010

Downloaded from Candiduria In Immunocompromised Individuals In A Tertiary Care Center In Northern India

Voriconazole Rationale for the EUCAST clinical breakpoints, version March 2010

Candida auris: an Emerging Hospital Infection

Potato Dextrose Agar Antifungal Susceptibility Testing for Yeasts and Molds: Evaluation of Phosphate Effect on Antifungal Activity of CMT-3

FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia

Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital

Cigna Drug and Biologic Coverage Policy

Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility

Antifungal Stewardship. Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul

Candidemia: New Sentinel Surveillance in the 7-County Metro

Antifungal Pharmacodynamics A Strategy to Optimize Efficacy

Nosocomial Candidemia in intensive care units of a tertiary care hospital, New Delhi, India

Susceptibilities of Candida spp. to Antifungal Agents Visualized by Two-Dimensional Scatterplots of Relative Growth

Received 24 September 2001/Returned for modification 2 February 2002/Accepted 31 May 2002

Fluconazole Susceptibility Profile of Candida isolates Recovered from Patients Specimens Admitted to Yazd Central Laboratory

Multilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis

Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan

Speciation and susceptibility testing of Candida isolates from vaginal discharge

Received 5 August 2004/Accepted 26 September 2004

Received 7 March 2002/Returned for modification 16 April 2002/Accepted 13 June 2002

Current options of antifungal therapy in invasive candidiasis

5-Fluorocytosine resistance in clinical isolates of cryptococcus neoformans

The Effect of Dimethyl Sulfoxide DMSO on the Growth of Dermatophytes

Prevalence of Oral Thrush Yeasts among School Children with special emphasis of Fluconazole antifungal drug

ESCMID Online Lecture Library. by author

on December 11, 2018 by guest

Efficacy of a Novel Echinocandin, CD101, in a Mouse Model of Azole-Resistant Disseminated Candidiasis

How Can We Prevent Invasive Fungal Disease?

Rapid Species Identification and Antifungal Susceptibility Testing of Candida Isolated from Different Hospital Acquired Infections by VITEK 2 System

The Evolving Role of Antifungal Susceptibility Testing. Gregory A. Eschenauer and Peggy L. Carver

ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS

Use of Antifungal Drugs in the Year 2006"

Intracellular Activity of Voriconazole, Fluconazole, and Itraconazole Against Candida albicans

Antifungal Potential of Disulfiram

This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.

Research Article In Vitro Susceptibility of Candida Species to Four Antifungal Agents Assessed by the Reference Broth Microdilution Method

Rapid Antifungal Susceptibility Determination for Yeast Isolates by Use of Etest Performed Directly on Blood Samples from Patients with Fungemia

Transcription:

OnLine Journal of Biological Sciences 10 (2): 109-113, 2010 ISSN 1608-4217 2010 Science Publications Susceptibility of Candida Species Isolated From HIV Infected and Newborn Candidaemia Patients to Amphotericin B Saikat Basu, Debasrita Chakraborty and Satadal Das Department of Microbiology and Serology, Peerless Hospital and BK Roy Research Centre, 76 Satyen Roy Road, Kolkata-700094, India Abstract: Problem statement: HIV infected and neonatal candidaemia is a serious condition where proper selection of the antifungal agent is the key factor in the prognosis of the disease. Thus in this study susceptibility of Candida species to Amphotericin B was explored in such patients. Approach: Forty different Candida isolates obtained from blood culture of such candidaemia cases were tested for Amphotericin B susceptibility by disc diffusion method and by microdilution method. Results: There was a good correlation between low MIC values and large inhibition zones among most isolates as expected, particularly with 24 h reading. Several outlier data were also observed during the study. After analysis it was found that 24 h microdilution method results were better for interpretation of susceptibility results. Conclusion: Microdilution method is the reliable method for susceptibility testing of Candida isolates from HIV infected and neonatal candidaemia patients to Amphotericin B. Key words: Candidaemia, disc diffusion, microdilution INTRODUCTION Candidiasis is a common opportunistic infection in immunocompromised hosts and candidaemia causes significant morbidity and mortality in this group of patients (Richards et al., 1999). In recent past, lifethreatening mycoses has been increasing in individuals with compromised immune system and there is a dramatic change in the incidence of different Candida spp. in candidiasis. During last five years (Nguyen et al., 1996). In general Candida albicans is the most abundantly isolated Candida spp. implicated in fungal infections. However, in South East Asian countries incidence of Candida albicans infection had gradually been decreased, while incidence of Candida tropicalis infection was almost equivalently increased during the same period, most of which were fluconazole resistant (Chakrabarty et al., 1999). Antifungal agents currently available for clinical use belong to three major classes: Polyenes, azoles and 5-flucytosine (Martin et al., 1992). Optimally, antifungals should exhibit selective toxicity; they should be able to inhibit the growth of the fungus without adversely affecting the host. It has been noticed that emergence of resistant strains of Candida spp. is due to extensive use of fluconazole as prophylactic treatment in immunocompromised patients (Rattan, 1999). Even today, Amphotericin B is the gold standard medicine for treating invasive mycoses. It is concentrated primarily in liver and spleen; lesser amounts are accumulated in kidneys and lungs. The primary tissue reservoirs elute the drug back into the blood as plasma levels of the drug fall (Baginski and Czub, 2009). Amphotericin B is selectively taken up into the reticuloendothelial system and concentrated in the reservoir organs. Lipid-rich particles with Amphotericin B are also ingested by phagocytic monocytes; this process helps in targeting the drug to sites of infection or inflammation (Jill and Richard, 2002; Czumb and Baginksi, 2009). In vitro, Amphotericin B demonstrated potent and broadspectrum fungicidal activity against clinically relevant fungi including Candida spp. The M27-A2, NCCLS, USA (Second Edition) is a reference standard protocol for susceptibility testing of Candida spp. It is being developed through a consensus process to facilitate the agreement among laboratories in measuring the susceptibility of yeasts to antifungal agents. The NCCLS method for in vitro susceptibility testing is essential for standardization and to improve inter-laboratory reproducibility, it is difficult to use for all organisms or for routine use in clinical laboratories (National Committee for Clinical Laboratory Standards, 2002). Alternative methods such Corresponding Author: Satadal Das, Department of Microbiology and Serology, Peerless Hospital and BK Roy Research Centre, 76 Satyen Roy Road, Kolkata-700034, India Tel: +91-09831092130/033-2462 2394 Fax: 91(33) 2462 0766 109

as the agar-based Disc Diffusion (DD) method are preferable because they are simple and cost effective. The disease candidaemia is diagnosed when there is isolation of Candida spp. from one or more blood specimens (Edmond et al., 1999). Although oropharyngeal candidiasis being the most common fungal infection affecting patients with HIV and AIDS, candidaemia is most frequent in HIV infected adults particularly with borderline-stage AIDS (CD4+ counts <50 cells mm 3 ) and after extensive prior therapy with Amphotericin B. The frequent use of azole in HIV-infected patients compels Amphotericin B to be used as the first line antifungal agent when candidaemia sets in (Abgrall et al., 2001). Thus in this study, the applicability of the DD method for testing the susceptibility of Candida species to Amphotericin B was compared with the results of the broth microdilution method of the NCCLS (M-27-A2, NCCLS, USA) for Candida spp. strains isolated from blood of HIV-infected patients and some neonates, the two most susceptible groups for candida infection (Cuenca-Estrella et al., 2002). MATERIALS AND METHODS Candida spp. Isolates from blood culture: All Candida spp. were isolated from candidaemia patients with HIV infection (65%) and from neonates (35%). Blood cultures of patients were done in automated blood culture system (Becton Dickinson, BD, BACTEC 9050) in MYCO/F-Lytic bottles. A total of 40 clinical Candida isolates and 3 international control strains comprising of Candida albicans (8), Candida tropicalis (18), Candida glabrata (10) and Candida krusei (4) were taken to study their antifungal susceptibility. All the isolates were stored in cryogenic vials at -70 C as recommended (Espinel-Ingroff et al., 2004). Species identification were done by germ-tube test, colonial study on Corn Meal Agar (CMA) with 1% Tween 80/trypan blue, on candida chromogenic media and by carbohydrate assimilation, fermentation tests. OnLine J. Biol. Sci., 10 (2): 109-113, 2010 Blue Dye (GMB) Medium. Zone diameters (in mm) for the zone of complete inhibition were determined after 24 and 48 h of incubation at 35 C and compared with MICs determined by the M27-A2, NCCLS, USA (Second Edition) MD method. All the tested isolates showed good growth rates under these conditions which is a mandatory requirement under this protocol (Lozano-Chiu et al., 1999). Microdilution method: The antifungal stock solutions were made of standard antifungal powder of Amphotericin B (Obtained from Himedia, India). Its generic name was Amphotericin (Molecular formula- C 47 H 73 NO 17 and Molecular weight-924.1) with potency of 750 mcg mg 1. The inoculum suspensions were prepared as instructed in M27-A2, NCCLS, USA (Approved Standard Second Edition) (National Committee for Clinical Laboratory Standards, 2002). Method for Antifungal Disc Diffusion Susceptibility Testing of Yeasts: Propose Guideline M44-A.NCCLS, Wayne, PA., USA). Final concentrations of Amphotericin B were 0.0313-16 mcg ml 1 (The concentrations were 0.0313, 0.0625, 0.125, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0 and 16.0 mcg ml 1 ). To dilute the stock solution DMSO was used. These microwells were incubated at 35 C and MIC endpoints were determined after 24-48 h. The MICs of Amphotericin B were read by Thermo multiskan reader (Vantaa, Finland) as the lowest concentration that caused a significant diminution of growth compared with the control growth well. The medium used in this test was RPMI 1640, the endpoint was considered as a prominent decrease in turbidity corresponding to ~50% inhibition in growth as determined spectrophotometrically (Bannatyne and Cheung, 1977; Rodriguez-Tudela et al., 1996). It is demonstrated that the most reliable testing criteria for Candida are the use of RPMI broth and a prominent inhibition MIC endpoint. The two types of MICs were determined in this study, these were MIC 50 (MIC that inhibits 50% of the study strain) and MIC 90 (MIC that inhibits 90% of the study strain). For both methods an arbitrary break point had to be Two types of susceptibility testing-dd method: This established. Isolates with Diameter inhibition Zone test was done using Amphotericin B discs purchased (ZD) of <16 mm and MICs 16 mcg ml 1 were from Himedia, India manufactured according to the M considered to have high MIC values and those isolates 44-A, NCCLS, USA guidelines (National Committee with MICs of <16 mcg ml 1 and Diameter inhibition for Clinical Laboratory Standards, 2004). Method for Zone (ZD) 16 mm were considered to have low MIC Antifungal Disc Diffusion Susceptibility Testing of values. Yeasts: Propose Guideline M44-A.NCCLS, Wayne, For quality control three international strains PA., USA). The drug concentration of the discs was 20 were used-candida albicans (ATCC 10231), mcg disc 1. According to the guidelines, the medium Candida tropicalis (ATCC 750), Candida krusei required for the disc diffusion test was Mueller-Hinton (ATCC 6258) in every batch tested for antifungal Agar with 2% Glucose and 0.5 mcg ml 1 Methylene susceptibility (National Committee for Clinical 110

Laboratory Standards, 2002; 2004). Method for Antifungal Disc Diffusion Susceptibility Testing of Yeasts: ProposeGuidelineM44-A.NCCLS, Wayne, PA., USA). Statistical analysis of this study: Arithmetic Mean (AMs) and MIC ranges were calculated in each genusspecies combination to evaluate the comparative study between the disc diffusion and broth microdilution methods. The Mean, Standard deviation, Standard error of Mean were calculated in the data sets of different types of variables. As in this method paired data were obtained, so paired t tests of every possible combination were analyzed. The linear regression analysis was done in between the DD method and the MD method of antifungal susceptibility testing. Statistical analysis was calculated using Graph Pad and Vassar software. RESULTS There was no significant difference of susceptibility zones by DD method measured at 24 and 48 h (Table 1). Out of four species, Candida albicans and Candida glabrata showed high susceptibility zones (AM 18 mm) but Candida tropicalis and Candida krusei showed smaller zones (AM <13 mm) in the DD method (Table 2 and 3). Similarly, AM and ranges of various Candida species studied by micro dilution method was expressed as MIC 50. (MIC that inhibits 50% of study strains), MIC 90 (MIC that inhibits 90% of study strains) and their ranges are given in Table 2 and 3. In this study Amphotericin B exhibited high antifungal activity against all tested Candida species (IC 50 2 mcg ml 1 in most cases) by the micro dilution method and in this method all species have showed high sensitivity ranges compared to DD method. Paired t test value in between MIC 50 and MIC 90 in 24 h: The two tailed P value was less than 0.0001. By conventional criteria, this difference was considered to be extremely statistically significant. The standard error of difference was 0.168. Table 1: Susceptibility testing results determined by disc diffusion (AM and range) of Amphotericin B Species Incubation Inhibition AM (No. of isolates) period (h) zone (mm) (range) Candida albicans (8) 24 18 16-21 48 18 17-22 Candida tropicalis (18) 24 11 10-13 48 11 11-14 Candida glabrata (10) 24 21 18-22 48 21 19-23 Candida krusei (4) 24 11 8-14 48 11 9-15 Total (40) 24 15 8-21 48 15 9-23 AM: Arithmetic Mean OnLine J. Biol. Sci., 10 (2): 109-113, 2010 111 Paired t test value in between MIC 50 and MIC 90 in 48 h: The two tailed P value was less than 0.0001. By conventional criteria, this difference was considered to be extremely statistically significant. The standard error of difference was 0.210. A good correlation was observed between low MIC values and large inhibition zones for most of the organism tested as expected. The correlation was better in between results of MD 24/DD 24 h than results of MD 48/DD 24 h (r = -0.334 and r = -0.270, respectively) (Fig. 1a and b). There were some aberrant results with few isolates having low MIC ranges after 48 h of incubation shown small inhibition zones after 24 h and having high MIC ranges after 24 h of incubation but showing high inhibition zones after 48 h. Thus it was found that MD is a reliable method for susceptibility testing of Candida isolates to Amphotericin B in comparison to DD susceptibility testing. Most isolates with MIC sec 2 mcg ml 1 had >16 mm inhibition zones. However, there were few isolates of C. tropicalis, C. glabrata and C. krusei where this was not applicable. These isolates had inhibition zone of <13 mm but they had the MIC values of 0.25 mcg ml 1. On the other hand, few isolates of C. glabrata and C. albicans have >20 mm zones but have 2 mcg ml 1 MIC values. When susceptibility of 24 h DD was compared with 48 h MD (Fig. 1b) there were few isolates which had the MIC values of 0.25 mcg ml 1 but low ZD (<13 mm). The best correlation (95.5%) was observed between susceptibility results of MD 24 and DD 48 h. The percentage of false resistance/susceptibility was low in case of results with 24 MD 48 h 1 DD. Table 2: The suceptibility of Candida spp. against Amphotericin B determined by micro dilution method (MIC 50, MIC 90 and range) after 24 and 48 h of incubation Species Incubation MIC 50 MIC 90 Range (No. of isolates) period (h) (mcg ML 1 ) (mcg ml 1 ) (mcg ml 1 ) Candida albicans 24 1.22 2.80 1.0-4.00 (8) 48 1.22 3.20 1.0-4.00 Candida tropicalis) 24 0.86 3.26 0.25-4.0 (18) 48 0.84 3.90 0.25-4.0 Candida glabrata 24 0.82 2.30 0.5-4.00 (10) 48 0.86 2.80 0.5-4.00 Candida krusei (4) 24 1.20 3.20 0.5-4.00 (4) 48 1.20 3.80 0.5-4.00 Total (40) 24 0.97 2.90 0.5-4.00 48 0.96 3.50 0.5-4.00 MIC 50: 50% inhibition of growth; MIC 90: 90% inhibition of growth; AM: Arithmetic Mean Table 3: Susceptibility testing results after 24 and 48 h (Mean ± SD ± SEM) MIC and DD types N (Total no.) Mean SD SEM MIC 50 in 24 h 43 0.9712 0.8777 0.1338 MIC 90 in 24 h 43 2.9070 1.3419 0.2046 MIC 50 in 48 h 43 0.9653 0.8817 0.1345 MIC 90 in 48 h 43 3.5349 1.7368 0.2649 DD in 24 h 43 14.650 4.1100 0.6300 DD in 48 h 43 15.600 4.0900 0.6200

OnLine J. Biol. Sci., 10 (2): 109-113, 2010 method with 24 h susceptibility zone sizes was less significant than the previous combination (Ramirez et al., 2006). CONCLUSION Fig. 1a: Scatterogram showing relationship of 24 h DD zones of inhibition with 24 h MIC 90 values. The regression equation was y = 17.63-1.02x, r = -0.334, r 2 = 0.111 The above results suggested that the MD method should be used for testing the susceptibility of Candida spp. isolated from blood to Amphotericin B and as it is possible to get the result in spectrophotometric reading within 24 h, it may help in prevention of many deaths of patients suffering from candidaemia (Menichetti et al., 1994). As most of the candidaemia patients are associated with immunosuppression, it is necessary for the physicians to choose the perfect antifungal drug as soon as possible where MD method appears to be very helpful (Petri et al., 1997). However, there is a need for further studies on Candida strains with high MIC values against Amphotericin B. In developing countries like India it is also important to set up quality control parameters in different clinical laboratories in relation to in vitro susceptibility test by microdilution method which is reliable and better than Disc diffusion method. Fig. 1b: Scatterogram showing relationship of 24 h DD zones of inhibition with 48 h MIC90 values. The regression equation was y = 16.91-0.64x, r = -0.270, r 2 = 0.073 DISCUSSION ACKNOWLEDGMENT We are most grateful to the Managing Director of Peerless Hospital and BK Roy Research Centre for giving us funds and clinical data. REFERENCES Abgrall, S., I. Charreau, V. Joly, J. Bloch and J. Reynes, 2001. Risk factors for esophageal candidiasis in a large cohort of HIV-infected patients treated with The ability of the MD method to express the true nucleoside analogues. Eur. J. Clin. Microbiol. susceptibility of an individual isolate within 24 h is its Infect. Dis., 20: 346-349. DOI: great advantage but it has got a slight disadvantage in 10.1007/s100960100497 relation to its complex preparatory steps. On the Baginski, M. and J. Czub, 2009. Amphotericin B and Its contrary, the DD method is less time-consuming and new derivatives-mode of action. Curr. Drug could be a method of choice in a routine clinical Metab., 10: 459-69. PMID: 19689243 laboratory but chance of false positive results are Bannatyne, R.M. and R. Cheung, 1977. Comparative much higher than MD method (Lozano-Chiu et al., susceptibility of Candida albicans to amphotericin 1999). Thus, MD method appears to be superior to DD B and amphotericin B methyl ester. Antimicrob. method. Agents Chemother, 12: 449-450. PMCID: Our aim to find out a comparative data in relation PMC429943 to an agar-based method and broth MD technique in Chakrabarty, A., S. Singh and S. Das, 1999. Changing yeast was thus ended with a conclusive result. face of nosocomial candidaemia. Indian J. Med. Our conclusion is that the MD method is a very Microbiol., 17: 160-166. useful and perfect method than the DD method was also Cuenca-Estrella, M., W. Lee-Yang and M.A. Ciblak, supported by the regression analysis (Fig. 1a and b) 2002. Comparative evaluation of NCCLS M27-A between MIC values in 24 h broth MD method with and EUCAST broth microdilution procedures for 24 h susceptibility zone sizes. In the same analysis, the antifungal susceptibility testing of Candida species. correlation between MIC values in 48 h broth MD Antimicrob. Agents Chemother., 46: 3644-3647. 112

OnLine J. Biol. Sci., 10 (2): 109-113, 2010 Czumb, J. and M. Baginksi, 2009. Amphotericin B and its new derivatives mode of action. Curr. Drug Metab., 10: 459-469. PMID: 19689243 Edmond, M.B., S.E. Wallace and D.K. McClish., 1999. Nosocomial bloodstream infections in United States hospital: A three-year analysis. Clin. Infect. Dis., 29: 23944. Espinel-Ingroff, A., D. Montero, E. Martin-Mazuelos, 2004. Long-term preservation of fungal isolates in commercially prepared cryogenic microbank vials. J. Clin. Microbiol., 42: 12579. DOI: 10.1007/s12223-009-0036-3 Jill, A.M. and T. Richard, 2002. liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother., 49: 21-30. Lozano-Chiu, M., W.N. Page and L.P. Victor, 1999. Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991. J. Clin. Microbiol., 37: 1625-1627. Martin, E., P. Parras and M.C. Lozano, 1992. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocystosine, ketoconazole, fluconazole and itraconazole. Chemotherapy, 38: 335-339. PMID: 1337508 Menichetti, F., A. Del Favero, P. Martino, G. Bucaneve and A. Micozzi et al., 1994. Preventing fungal infection in neutropenic patients with acute leukemia: Fluconazole compared with oral amphotericin B. The GIMEMA infection program. Ann. Intern. Med., 120: 913-918. PMID: 8172437 National Committee for Clinical Laboratory Standards, 2002. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard. M27-A2.NCCLS, Wayne, PA, USA. http://www.clsi.org/source/orders/free/m27- S3.pdf National Committee for Clinical Laboratory Standards, 2004. Method for Antifungal Disc Diffusion Susceptibility Testing of Yeasts: Propose Guideline M44-A.NCCLS, Wayne, PA., USA http://www.clsi.org/source/orders/free/m51-p.pdf Nguyen, M.H., J.E. Peacock and A.J. Morris, 1996. The changing face of candidemia: Emergence of non- Candida albicans species and antifungal resistance. Am. J. Med., 100: 617-623. DOI: 10.1016/S0002-9343(95)00010-0 Petri, M.G., J. Konig and H.P. Moecke, 1997. Epidemiology of invasive mycosis in ICU patients: A prospective multicenter study in 435 nonneutropenic patients. Intens. Care Med., 23: 317-325. PMID: 9083235 Ramirez, M., M.C. Serrano, C. Castro, E. Lopez and C. Almeida et al., 2006. Comparative study of disc diffusion and microdilution methods in susceptibility testing of micafungin against Candida species. J. Antimicrob. Chemother, 58: 861-863. DOI: 10.1093/jac/dk1335 Rattan, A., 1999. Antifungal susceptibility testing. Indian J. Med. Microbiol., 17: 125-128. PMID: 16912435 Richards, M.J., J.R. Edwards, D.H. Culver and R.P. Gaynes, 1999. Nosocomial infections in medical intensive care units in the United States. Crit. Care Med., 27: 887-892. DOI: 10.1086/501795 Rodriguez-Tudela, J.L., J. Berenguer, V. Martinez- Suarez and R. Sanchez, 1996. Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro susceptibility testing of amphotericin B, flucytosine and fluconazole against Candida albicans. Antimicrob. Agents Chemother., 40: 1998-2003. 113